Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis (B-REACH)
sunnuntai 30. elokuuta 2026 päivittänyt: JinjunChen, The Second Affiliated Hospital of Chongqing Medical University
Efficacy and Safety of Mazdutide Injection for the Treatment of Overweight Patients With Compensated Cirrhosis and Clinically Significant Portal Hypertension
Obesity and metabolic abnormalities accelerate decompensation in compensated cirrhosis, driven by clinically significant portal hypertension (CSPH, HVPG≥10 mmHg). Lifestyle-induced weight loss can lower portal pressure, but pharmacological options are limited. Mazdutide, a dual GLP-1/glucagon receptor agonist, has proven weight-loss and glycaemic benefits, yet its safety and efficacy in cirrhosis with portal hypertension are unknown. This investigator-initiated, single-arm, open-label, exploratory trial evaluates whether mazdutide can safely reduce portal pressure in overweight patients with compensated cirrhosis and CSPH.
The main questions it aims to answer are:
Does 16-week mazdutide treatment reduce HVPG (percentage change from baseline)? What adverse events occur, and is the drug tolerated?
Participants will:
Receive mazdutide SC injection once weekly for 16 weeks, titrated from 2 mg to 4 mg to 6 mg (if tolerated), with dose adjustment for intolerance.
Undergo HVPG at baseline and week 16 (primary endpoint). Have FibroScan® (liver/spleen stiffness, CAP) at baseline and weeks 4, 8, 12, 16.
Provide blood samples for liver, renal, glucose, lipid, and coagulation tests at each visit.
Undergo body composition, handgrip strength, and nutritional assessments to monitor muscle mass.
Attend clinic visits every 4 weeks during treatment and one follow-up visit 4 weeks post-treatment.
Key eligibility: Adults 18-75 with compensated cirrhosis (viral, MASLD, or alcohol-related), HVPG≥10 mmHg, BMI≥28 or ≥26 with comorbidities, stable weight, and stable carvedilol/propranolol if used. Exclude prior decompensation, HCC, CTP≥B8, eGFR<60, mazdutide contraindications, active infection, uncontrolled hepatitis, portal vein thrombosis, etc.
Endpoints: Primary - % change in HVPG. Secondary - HVPG response (≥10% decrease or <10 mmHg), decompensation events, treatment discontinuation due to AEs. Exploratory - changes in stiffness, liver fat, metabolic parameters, body composition, nutrition.
Safety: AEs (CTCAE v5.0), labs, vitals, with special monitoring for GI symptoms, dehydration, renal function, hepatic encephalopathy, muscle loss, pancreatitis, and gallbladder events.
Sample size and analysis: 50 patients. Primary endpoint analysed by paired t-test or Wilcoxon (α=0.05, two-sided) in FAS and PPS. Secondary endpoints mainly descriptive; key secondary tested for support. Subgroup analyses planned if feasible.
Study duration: 20 weeks (2-week screening, 16-week treatment, 4-week follow-up). Conducted at Second Affiliated Hospital of Chongqing Medical University, China. Ethics approved, informed consent required. This study will provide first evidence on mazdutide for portal hypertension in overweight cirrhosis.
Tutkimuksen yleiskatsaus
Tila
Ei vielä rekrytointia
Interventio / Hoito
Opintotyyppi
Interventio
Ilmoittautuminen (Arvioitu)
50
Vaihe
- Ei sovellettavissa
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Ei
Kuvaus
Inclusion Criteria:
- Aged 18 to 75 years (inclusive), male or female.
- Documented etiology of chronic liver disease, limited to chronic hepatitis B, chronic hepatitis C, metabolic dysfunction-associated steatotic liver disease (MASLD), or alcohol-related liver disease.
- Cirrhosis confirmed by imaging (ultrasound, CT, or MRI), or pathology showing F3/F4 fibrosis, or liver stiffness measurement (LSM) ≥15 kPa by vibration-controlled transient elastography (VCTE).
- Hepatic venous pressure gradient (HVPG) ≥10 mmHg.
- Body mass index (BMI) ≥28 kg/m², or BMI ≥26 kg/m² with at least one weight-related comorbidity (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea syndrome).
- Stable body weight over the past 6 months, defined as weight fluctuation <3 kg.
- For patients with gastroesophageal varices requiring carvedilol or propranolol, the dose must have been stable for at least 3 months with no planned dose adjustments during the trial.
- Voluntarily signed informed consent form.
Exclusion Criteria:
- Concurrent hepatocellular carcinoma or other malignancies (excluding cured basal cell carcinoma of the skin).
- Prior history of clinically significant decompensation events (grade 2/3 ascites, overt hepatic encephalopathy, or gastroesophageal variceal bleeding).
- Progressive jaundice during the screening period.
- Hepatic impairment defined as Child-Turcotte-Pugh (CTP) score ≥B8 at screening.
- Moderate to severe renal impairment (eGFR <60 mL/min) or current renal replacement therapy.
- Contraindications to mazdutide: known allergy, personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2.
- Previous or current use of other weight-loss interventions (e.g., bariatric surgery, endoscopic bariatric procedures, other weight-loss drugs).
- Participation in another interventional clinical trial within 3 months prior to screening, or previous treatment with mazdutide.
- Active infection at screening.
- For alcohol-related cirrhosis: alcohol abstinence <6 months or ongoing alcohol consumption. For viral cirrhosis (hepatitis B/C): failure to achieve virologic suppression (HBV-DNA <100 IU/mL for hepatitis B; for hepatitis C, HCV-RNA below the lower limit of detection after >12 weeks of antiviral therapy).
- Prior portal-systemic shunt surgery (e.g., splenectomy).
- Previous orthotopic liver transplantation.
- Known portal vein thrombosis.
- Contraindications to trial assessments, e.g., inability to undergo HVPG measurement.
- Pregnancy or breastfeeding, or unwillingness to use investigator-approved contraception during the study and for 6 months after the study end.
- Psychiatric or cognitive disorders that interfere with study compliance.
- Any other condition judged by the investigator to make the participant unsuitable for participation.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Experimental: Mazdutide (2/4/6 mg Titration) SC QW
|
Mazdutide injection is a sterile, clear to almost colorless liquid formulated for subcutaneous administration.
It is supplied in three fixed-dose strengths for this study: 2 mg/0.5 mL, 4 mg/0.5 mL, and 6 mg/0.5 mL.
Participants assigned to this arm receive once-weekly subcutaneous injections over a 16-week active treatment period.
The regimen begins with a forced dose-titration phase: 2 mg weekly for the first 4 weeks, followed by 4 mg weekly for the next 4 weeks, and then 6 mg weekly for the final 8 weeks, provided the preceding dose is tolerated.
In cases of treatment-emergent adverse events (CTCAE grade ≥2 or intolerable grade 1), the investigator may temporarily withhold the dose, step down to the next lower dose level (6 mg→4 mg→2 mg), or permanently discontinue the drug.
After symptom resolution, gradual re-escalation (2 mg→4 mg→6 mg) may be attempted at the investigator's discretion.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Percentage Change in Hepatic Venous Pressure Gradient (HVPG) from Baseline
Aikaikkuna: Baseline (screening, Day -14 to -1) to Week 16 (End of Treatment, Day 112 ± 3 days)
|
Percentage change in HVPG (measured in mmHg) from baseline to week 16.
HVPG is calculated as the difference between wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP), measured via hepatic vein catheterization under fasting conditions.
A negative percentage change indicates a reduction in portal pressure.
HVPG measurements will be performed in triplicate through the same hepatic vein, preferably in the morning, at baseline (screening period) and at week 16 (end-of-treatment visit, Day 112).
All measurements follow a standardized procedure by experienced operators (≥25 HVPG measurements annually).
|
Baseline (screening, Day -14 to -1) to Week 16 (End of Treatment, Day 112 ± 3 days)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Proportion of Participants Achieving HVPG Response
Aikaikkuna: Baseline to Week 16 (End of Treatment, Day 112 ± 3 days)
|
Proportion of participants with a reduction in HVPG of ≥10% from baseline, or a reduction to an absolute value of <10 mmHg at week 16.
HVPG is measured via hepatic vein catheterization in triplicate under fasting conditions.
|
Baseline to Week 16 (End of Treatment, Day 112 ± 3 days)
|
|
Incidence of Hepatic Decompensation Events
Aikaikkuna: Baseline up to Week 16 (End of Treatment)
|
Number of participants experiencing any first or recurrent decompensation event during the treatment period, including: overt ascites (requiring paracentesis or diuretic escalation), overt hepatic encephalopathy (West Haven grade ≥2), or gastroesophageal variceal bleeding (confirmed by endoscopy or imaging).
|
Baseline up to Week 16 (End of Treatment)
|
|
Treatment Discontinuation Due to Adverse Events
Aikaikkuna: Day 1 (First dose) to Week 16 (End of Treatment)
|
Number of participants who permanently discontinue study drug due to any adverse event (AE) during the 16-week treatment period, regardless of causality.
Reasons for discontinuation will be summarized by system organ class and preferred term.
|
Day 1 (First dose) to Week 16 (End of Treatment)
|
|
Change in Liver and Spleen Stiffness
Aikaikkuna: Baseline to Week 16 (End of Treatment, Day 112 ± 3 days)
|
Absolute change (kPa) and percentage change in liver stiffness measurement (LSM) and spleen stiffness measurement (SSM) from baseline to week 16, assessed by vibration-controlled transient elastography (VCTE™, FibroScan®) under fasting conditions.
|
Baseline to Week 16 (End of Treatment, Day 112 ± 3 days)
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Liver stiffness measured by VCTE
Aikaikkuna: Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
Change from baseline in liver stiffness assessed by Vibration-Controlled Transient Elastography (VCTE).
Unit of measure: kPa
|
Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
|
Spleen Stiffness measured by VCTE
Aikaikkuna: Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
Change from baseline in spleen stiffness assessed by Vibration-Controlled Transient Elastography (VCTE).
Unit of measure: kPa.
|
Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
|
Liver Fat Content measured by Controlled Attenuation Parameter (CAP)
Aikaikkuna: Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
Change from baseline in liver fat content assessed by CAP.
Unit of measure: dB/m.
|
Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
|
Liver Function Tests (ALT, AST, Bilirubin, Albumin)
Aikaikkuna: Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
Change from baseline in serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total and direct bilirubin, and albumin.
These assessments have different units (ALT/AST in U/L; bilirubin in μmol/L or mg/dL; albumin in g/L) and will be reported individually without aggregation into a composite value.
|
Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
|
Coagulation Function (PT, INR, APTT)
Aikaikkuna: Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
Change from baseline in prothrombin time (PT, in seconds), international normalized ratio (INR, dimensionless ratio), and activated partial thromboplastin time (APTT, in seconds).
These assessments with different units will be reported separately.
|
Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
|
Renal Function (eGFR)
Aikaikkuna: Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
Change from baseline in estimated glomerular filtration rate calculated using the CKD-EPI or MDRD formula.
Unit of measure: mL/min/1.73m².
|
Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
|
Body Composition Indices (BMI, Waist-to-Hip Ratio, Waist-to-Height Ratio)
Aikaikkuna: Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
Change from baseline in body composition indices.
Note on aggregation: Weight (kg) and height (m) will be combined to calculate BMI (kg/m²); waist circumference (cm) and hip circumference (cm) will be combined to calculate waist-to-hip ratio and waist-to-height ratio (both expressed as dimensionless ratios).
All derived indices will be reported individually.
|
Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
|
Fasting Glucose and Lipid Profile
Aikaikkuna: Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
Change from baseline in fasting plasma glucose, total cholesterol, triglycerides, LDL-C, and HDL-C.
All assessments share the same unit of measure (mmol/L or mg/dL, depending on local laboratory standard) and will be reported as separate numerical values.
|
Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
|
Uric Acid
Aikaikkuna: Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
Change from baseline in serum uric acid.
Unit of measure: μmol/L or mg/dL (as per local laboratory).
|
Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
|
Urine Protein
Aikaikkuna: Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
Change from baseline in urine protein concentration.
Unit of measure: mg/dL or g/24h (as per collection method).
|
Baseline to weeks 4, 8, 12, and 16 (Days 28, 56, 84, 112; ±3 days)
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Tiistai 1. syyskuuta 2026
Ensisijainen valmistuminen (Arvioitu)
Torstai 31. toukokuuta 2029
Opintojen valmistuminen (Arvioitu)
Torstai 31. toukokuuta 2029
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Torstai 20. elokuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Sunnuntai 30. elokuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Tiistai 1. syyskuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Tiistai 1. syyskuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Sunnuntai 30. elokuuta 2026
Viimeksi vahvistettu
Lauantai 1. elokuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 2026-IIT-SL-233
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
EI
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .